Journal Article10.1097/OGX.0B013E318247C6F7
Long-Term Persistence of Hormonal Adaptations to Weight Loss
Priya Sumithran,Luke A. Prendergast,Elizabeth Delbridge,K. Purcell,Arthur Shulkes,Adamandia Kriketos,Joseph Proietto +6 more
782
TL;DR: In this article, a 10-week weight-loss program for which a very low-energy diet was prescribed to 50 overweight or obese patients without diabetes was found to lead to significant reductions in levels of leptin, ghrelin, peptide YY, cholecystokinin, insulin, and pancreatic polypeptide.
read more
Abstract: Methods We enrolled 50 overweight or obese patients without diabetes in a 10-week weight-loss program for which a very-low-energy diet was prescribed. At baseline (before weight loss), at 10 weeks (after program completion), and at 62 weeks, we examined circulating levels of leptin, ghrelin, peptide YY, gastric inhibitory polypeptide, glucagon-like peptide 1, amylin, pancreatic polypeptide, cholecystokinin, and insulin and subjective ratings of appetite. Results Weight loss (mean [±SE], 13.5±0.5 kg) led to significant reductions in levels of leptin, peptide YY, cholecystokinin, insulin (P<0.001 for all comparisons), and amylin (P = 0.002) and to increases in levels of ghrelin (P<0.001), gastric inhibitory polypeptide (P = 0.004), and pancreatic polypeptide (P = 0.008). There was also a significant increase in subjective appetite (P<0.001). One year after the initial weight loss, there were still significant differences from baseline in the mean levels of leptin (P<0.001), peptide YY (P<0.001), cholecystokinin (P = 0.04), insulin (P = 0.01), ghrelin (P<0.001), gastric inhibitory polypeptide (P<0.001), and pancreatic polypeptide (P = 0.002), as well as hunger (P<0.001). Conclusions One year after initial weight reduction, levels of the circulating mediators of appetite that encourage weight regain after diet-induced weight loss do not revert to the levels recorded before weight loss. Long-term strategies to counteract this change may be needed to prevent obesity relapse. (Funded by the National Health and Medical Research Council and others; ClinicalTrials.gov number, NCT00870259.)
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Mechanisms of Diabetic Complications
TL;DR: The well validated, as well as putative mechanisms involved in the development of diabetic complications are discussed and new fields of research, which warrant further investigation as potential therapeutic targets of the future, will be highlighted.
2.5K
Mechanisms, Pathophysiology, and Management of Obesity
TL;DR: Treatments for obesity include behavioral therapy, pharmacotherapy, and bariatric surgery, and some sequelae of obesity are reversed with weight loss.
1.5K
Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
Caroline M. Apovian,Louis J. Aronne,Daniel H. Bessesen,Marie E. McDonnell,M. Hassan Murad,Uberto Pagotto,Donna H. Ryan,Christopher D. Still +7 more
TL;DR: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe the strength of recommendations and the quality of evidence.
Early developmental conditioning of later health and disease: physiology or pathophysiology?
Mark A. Hanson,Peter D. Gluckman +1 more
TL;DR: The extent to which DOHaD represents the result of the physiological processes of developmental plasticity, which may have potential adverse consequences in terms of NCD risk later, or whether it is the manifestation of pathophysiological processes acting in early life but only becoming apparent as disease later?
1K
Obesity in adults: a clinical practice guideline
Sean Wharton,David C.W. Lau,Michael Vallis,Arya M. Sharma,Laurent Biertho,Denise Campbell-Scherer,Kristi B. Adamo,Angela S. Alberga,Rhonda Bell,Normand G. Boulé,Elaine Boyling,Jennifer Brown,Betty Calam,Carol Clarke,Lindsay Crowshoe,Dennis Divalentino,Mary Forhan,Yoni Freedhoff,Michel Gagner,Stephen Glazer,Cindy Grand,Michael E. Green,Margaret Hahn,Raed Hawa,Rita Henderson,Dennis Hong,Pam Hung,Ian Janssen,Kristen Jacklin,Carlene Johnson-Stoklossa,Amy Kemp,Sara F. L. Kirk,Jennifer L. Kuk,Marie-France Langlois,Scott Lear,Ashley McInnes,David Macklin,Leen Naji,Priya Manjoo,Marie-Philippe Morin,Kara Nerenberg,Ian Patton,Sue Pedersen,Leticia Pereira,Helena Piccinini-Vallis,Megha Poddar,Paul Poirier,Denis Prud'homme,Ximena Ramos Salas,Christian F. Rueda-Clausen,Shelly Russell-Mayhew,Judy Shiau,Diana Sherifali,John L. Sievenpiper,Sanjeev Sockalingam,Valerie H. Taylor,Ellen L. Toth,Laurie Twells,Richard Tytus,Shahebina Walji,Leah Walker,Sonja Wicklum +61 more
TL;DR: Obesity is a complex chronic disease in which abnormal or excess body fat (adiposity) impairs health, increases the risk of long-term medical complications and reduces lifespan.
References
Serum Immunoreactive-Leptin Concentrations in Normal-Weight and Obese Humans
Robert V. Considine,Madhur K. Sinha,Mark L. Heiman,Aidas Kriauciunas,Thomas W. Stephens,Mark R. Nyce,Joanna P. Ohannesian,Cheryl C. Marco,Linda J. McKee,Thomas L. Bauer,Jose F. Caro +10 more
TL;DR: Serum leptin concentrations are correlated with the percentage of body fat, suggesting that most obese persons are insensitive to endogenous leptin production.
6.8K
Central nervous system control of food intake
TL;DR: A model is described that delineates the roles of individual hormonal and neuropeptide signalling pathways in the control of food intake and the means by which obesity can arise from inherited or acquired defects in their function.
Effects of the obese gene product on body weight regulation in ob/ob mice
Mary Ann Pelleymounter,Mary Jane Cullen,Mary Beth Baker,Randy Ira Hecht,Dwight Winters,Thomas C. Boone,Frank H. Collins +6 more
TL;DR: The data suggest that the OB protein regulates body weight and fat deposition through effects on metabolism and appetite.
4.4K
Gut hormone PYY 3-36 physiologically inhibits food intake
Rachel L. Batterham,Michael A. Cowley,Caroline J. Small,Herbert Herzog,Mark Cohen,C. L. Dakin,Alison M. Wren,Audrey E. Brynes,Malcolm J. Low,Mohammad A. Ghatei,Roger D. Cone,Stephen R. Bloom +11 more
TL;DR: In this paper, the authors showed that post-prandial elevation of PYY3-36 may act through the arcuate nucleus Y2R to inhibit feeding in a gut-hypothalamic pathway.
2.3K
Changes in Energy Expenditure Resulting from Altered Body Weight
TL;DR: Maintenance of a reduced or elevated body weight is associated with compensatory changes in energy expenditure, which oppose the maintenance of a body weight that is different from the usual weight, which may account for the poor long-term efficacy of treatments for obesity.
2K